Parsonex Advisory Services’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Parsonex Advisory Services's VRTX Position: Q2 2026 in Review
Parsonex Advisory Services sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 499 shares — an estimated $223K sold.
Parsonex Advisory Services first reported a position in VRTX in Q2 2025 and held it in 4 quarters. The position peaked at $467K in Q4 2025. 1,743 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Parsonex Advisory Services reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Parsonex Advisory Services sold 499 Vertex Pharmaceuticals shares in Q2 2026, an estimated $223K.
- Parsonex Advisory Services first reported a position in Vertex Pharmaceuticals in Q2 2025 and held it in 4 quarters.
- Parsonex Advisory Services's Vertex Pharmaceuticals position peaked at $467K in Q4 2025.
- 1,743 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Parsonex Advisory Services's 13F filing for Q2 2026, filed 10 Aug 2026.